The US Public Paid to Develop This COVID-19 Drug. It Will Cost $3,000 a Dose.

The American public helped pay for the development of remdesivir, a COVID-19 drug. That same American public will now be charged $3,000 for a treatment — a treatment that experts say costs less than $10 to produce.

Maker Of Coronavirus Trial Drug Remdesivir, Gilead Sciences. Inc., Reports Positive Data Coming From Trials

Gilead Sciences headquarters in Foster City, California. (Justin Sullivan / Getty Images)


This is a story of cause and effect — a tale of repeated and calculated public policy decisions that have now led to a predictable outcome.

This story begins twenty-five years ago, when the Clinton administration rescinded a rule that required pharmaceutical companies to charge Americans reasonable prices for medicines developed at government expense. Some progressive lawmakers tried to reinstate the rule, but Republicans and Democrats joined together to halt those initiatives.

In the ensuing years, the Obama administration refused Democratic lawmakers’ demand to invoke existing federal laws to force down the price of critical medicines. Meanwhile, the GOP also blocked legislation to let Medicare use its purchasing power to negotiate lower prices for prescription drugs.

This article is for subscribers only. Please login or subscribe to access our full archives and beautiful print and digital magazine starting at just $3 a month.